TIL Company Profile and Key Details

Instil Bio, Inc. (NASDAQ:TIL) closed at $8.60 USD, gaining $0.04 (0.47%) from the previous close of $8.56. The stock is currently mid-range between its 52-week high and low $5.67 and $42.79. With a market capitalization of about $58.32 million, Instil Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.05). Key stats such as the average daily volume over the past year has been around 124.98 thousand shares, volume is running light vs its 52-week average. Headquartered in Dallas, TX, Instil Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bronson Crouch, the company employs approximately 14 people and listed since March 19, 2021. Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.

TIL has shown weak momentum, losing -0.98% over the past week and -62.9% over the past quarter, though year-to-date performance is down -35.64%. Short-term trend indicators are bullishly aligned (SMA20 11.26%, SMA50 3.91%, SMA200 -52.04%). The stock’s 14-day RSI is 57.91 (neutral), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.99% below its high and over 58.55% above its low. Average 10-day trading volume of 17.35 thousand shares is below the 3-month average of 122.70 thousand, indicating normal recent market interest.

Instil Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$11.99. This means the shares are trading below this model’s fair value.

Instil Bio, Inc. generated EPS of -$11.39 over the past year. Five-year average earnings growth is -62.1%. The latest quarter delivered EPS of -$2.01. The next quarter is forecast at -$2.04. Next year's EPS is expected at $47.98. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $125.00 to $125.00. The high target offers 1353.49% upside. The low target suggests 1353.49% downside. The mean target is $125.00. This offers 1353.49% upside. Instil Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 0.53%. The prior quarter beat by 88.37%. Over the last six quarters, Apple has recorded several small beats. These include -24.67% in August 13, 2024.

Instil Bio, Inc. has 6.75 million shares outstanding. The public float is 3.31 million shares, elevated short interest at 23.74% of float. This equals 950.37 thousand shares. The short ratio is 7.11 days. Institutional investors hold 72.06% of the float. Insiders own 6.29%. Crouch Bronson holds 37.98 million shares, Curative Ventures V LLC has 37.98 million shares and Nielsen Jack has 12.49 million shares.